News

IR News & Topics

2024.11.20
SymBio Presents Research Results Showing Potential Use of Intravenous Brincidofovir in Combination with Immune Checkpoint Inhibitors as a Therapy for Malignant Lymphoma at the 66th the American Society of Hematology Annual Meeting
2024.11.05
Notice of Appointment of Executive Vice President, Corporate Officer and Global CMO
2024.10.31
Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
2024.10.23
SymBio presents data from Phase IIa clinical trial showing clinical efficacy of IV BCV in treating symptoms of adenovirus infection
2024.09.30
SymBio Reaches Settlement Agreement in Patent Infringement Litigation Related to TREAKISYM
2024.09.30
Analyst Report[Follow-up Report] (Fair Research)
2024.09.18
Key person interview: Updated the Page
2024.08.19
SymBio Initiates Phase 1b Clinical Trial of IV Brincidofovir in Patients with Lymphoma as a First in Human Study for Oncology
2024.08.14
中間決算説明会スクリプト（2024年12月期）(Japanese only)
2024.08.13
Article on 2024 1H Earnings Call Featured in Nikkei Biotech Online (Japanese only)

Source: Nikkei Biotech ONLINE, 2024.08.07

Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.

2024.08.08
2024年12月期中間決算説明会の動画を掲載しました。(Japanese only)
2024.08.05
中間決算説明会資料（2024年12月期）(Japanese only)
2024.08.02
Analyst Report[Flash report] (Shared Research)
2024.08.01
Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
2024.07.12
SymBio Pharmaceuticals Announces Publication of Research Showing Antiviral Drug Brincidofovir Inhibits Infectious Viral Production of Polyomavirus
2024.06.24
Confirmed Antitumor Effects of Brincidofovir in Peripheral T-Cell Lymphoma Suppression of the oncogenic MYC and Induction of Expression of Immunogenic Response Pathways
2024.06.11
SymBio Announces Enrollment of the First Patient of Phase 2a Clinical Trial of Intravenous Brincidofovir for Treatment of Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
2024.06.03
Notice of Appointment of Corporate Officer
2024.05.13
株主通信「SymBio VISION vol.25」(Japanese only)
2024.05.08
SymBio Announces Initiation of Phase 2a Clinical Trial (ATHENA) of Intravenous Brincidofovir for Treatment of Cytomegalovirus Infection after Hematopoietic Stem Cell Transplantation
2024.05.08
四半期報告書－第20期第1四半期(2024/01/01－2024/03/31) (Japanese only)
2024.05.07
Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2024 [Japanese GAAP]
2024.05.07
Revision to Earnings Forecast for FY 2024
2024.04.19
Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
2024.04.19
Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
2024.04.19
訂正臨時報告書(Japanese only)
2024.04.19
Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (5th Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
2024.04.08
Onconova Therapeutics and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc.
2024.04.03
Notice of Confirmation of the Terms and Conditions of the New Share Issue (5th Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (5th Allotment)
2024.04.03
Notice Regarding Adjustment of Exercise Price
2024.04.03
コーポレート・ガバナンスに関する報告書 2024/04/03(Japanese only)
2024.04.01
Notice of Personnel Changes at SymBio Pharma USA, Inc.
2024.03.29
事業計画及び成長可能性に関する事項(Japanese only)
2024.03.26
「動画で観るシンバイオ製薬」を更新しました。(Japanese only)
2024.03.26
第19期定時株主総会の動画を掲載しました。(Japanese only)
2024.03.25
臨時報告書(Japanese only)
2024.03.25
Notice of Shareholder Voting Results for the 19th Annual General Meeting of Shareholders
2024.03.25
Notice of Transfer of EU Orphan Designations of Brincidofovir
2024.03.22
Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
2024.03.22
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2024.03.22
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2024.03.18
Research results showing anti-proliferative activity of brincidofovir in B-cell lymphoma to be presented at the AACR Annual Meeting 2024
2024.03.18
Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (4th Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
2024.02.29
Notice of Confirmation of the Terms and Conditions of the New Share Issue (4th Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (4th Allotment)
2024.02.29
Notice Regarding Adjustment of Exercise Price
2024.02.26
Notice of Convocation of the 19th Ordinary General Meeting of Shareholders
2024.02.26
Information on Shareholders' Meeting: Updated the Page
2024.02.22
Notification of Amendment to the Articles of Incorporation
2024.02.20
Article on 2023 Earnings Call Featured in Nikkei Biotech Online (Japanese only)

Source: Nikkei Biotech ONLINE, 2024.02.15

Although Nikkei BP grants permission to use the articles, the content of the articles does not constitute a recommendation to purchase/invest in a specific company/organization or product/service.
Unauthorized reproduction, duplication, or electronic storage of the articles/photos/charts, etc. is prohibited.

2024.02.16
2023年12月期決算説明会の動画を掲載しました。(Japanese only)
2024.02.14
決算説明会資料（2023年12月期）(Japanese only)
2024.02.13
Preliminary Results of Phase 2a Clinical Trial of Intravenous Brincidofovir (IV BCV) in Immunocompromised Patients with Adenovirus Infection Selected for Oral Presentation at 50th Annual Meeting of the EBMT in Glasgow
2024.02.09
Analyst Report[Full report] (Shared Research)
2024.02.09
Notice of Recognition of Impairment Loss, and Differences between Consolidated Earnings Forecasts and Actual Results for FY2023
2024.02.08
Summary of Financial Statements for the Fiscal Year Ended December 31, 2023 [Japanese GAAP] (Consolidated)
2024.02.07
Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (3rd Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
2024.01.23
Preliminary Results of a Phase 2a Clinical Trial of Intravenous Brincidofovir (IV BCV) in Immunocompromised Patients with Adenovirus Infection Selected for Pediatric Best Abstracts at the 2024 Tandem Meetings of ASTCT and CIBMTR
2024.01.22
Notice Regarding Adjustment of Exercise Price
2024.01.22
Notice of Confirmation of the Terms and Conditions of the New Share Issue (3rd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (3rd Allotment)
2024.01.19
SymBio Granted Patent in Japan for Use of Intravenous Brincidofovir for Treatment of Adenovirus Infection and Infectious Disease
2024.01.16
株主様向け決算説明会への抽選によるご招待(Japanese only)
2024.01.10
株主通信「SymBio VISION vol.24」(Japanese only)
2023.12.20
Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (2nd Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
2023.12.11
SymBio Presents New Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
2023.12.04
Notice of Confirmation of the Terms and Conditions of the New Share Issue (2nd Allotment) through Third-Party Allotment based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (2nd Allotment)
2023.12.04
Notice Regarding Adjustment of Exercise Price
2023.11.17
Notice of Relocation of Head Office
2023.11.14
Analyst Report[Flash report] (Shared Research)
2023.11.14
四半期報告書－第19期第3四半期(2023/07/01－2023/09/30) (Japanese only)
2023.11.14
Summary of Consolidated Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
2023.11.14
Revision to Earnings Forecast and Reversal of deferred tax assets for FY 2023
2023.11.10
Notice of Completion of Payment for the New Share Issue through Third-Party Allotment (1st Allotment) based on the Agreement to Set up a STraight-Equity Issue Program (“STEP”)
2023.11.06
SymBio To Present Positive Data from Ongoing Phase 2a Study of IV Brincidofovir in Adenovirus Infection in Oral Presentation at the 65th American Society of Hematology (ASH) Annual Meeting
2023.10.25
Notice of Confirmation of the Terms and Conditions of the New Share Issue (1st Allotment) through Third-Party Allotment based on the Agreement to Sept up a STraight-Equity Issue Program (“STEP”) and Revision of Funds to be Raised through the New Share Issue (1st Allotment)
2023.10.25
Notice Regarding Adjustment of Exercise Price
2023.10.16
Onconova Therapeutics announces Encouraging Rigosertib Data in RDEB-associated SCC Presented at EADV as Late Breaker
2023.10.12
The Results of CRADA Study on Brincidofovir in Multiple Sclerosis Presented at the 9th Joint ECTRIMS-ACTRIMS Meeting
2023.10.06
Notice of Agreement to Set up a STraight-Equity Issue Program (“STEP”) and Issue New Shares through Third-Party Allotment
2023.08.29
Notice of Change of Global Chief Medical Officer and Appointment of Senior Vice President of SymBio Pharma USA, Inc.
2023.08.14
Revision to Development Plan for IV Brincidofovir for BK virus
2023.08.03
Summary of Consolidated Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
2023.08.03
Revision to Earnings Forecast for FY 2023
2023.07.20
Notice of Personnel Changes at SymBio Pharma USA, Inc.
2023.07.14
Analyst Report[Full report] (Shared Research)
2023.06.12
Presentation of the Results of Biomarker Research Predicting the Antitumor Effects of Brincidofovir at the 17th ICML
2023.06.07
Onconova Therapeutics Announces Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting
2023.05.29
IV Brincidofovir in Adenovirus Infection achieved POC in Phase 2 Clinical Trial
2023.05.10
Onconova Therapeutics announces presentation of an overview of its investigator-sponsored clinical program evaluating rigosertib monotherapy in RDEB-associated SCC at the ISID International Epidermolysis Bullosa Symposium in Osaka
2023.04.27
Analyst Report[Flash report] (Shared Research)
2023.04.27
Summary of Consolidated Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2023 [Japanese GAAP]
2023.04.24
SymBio enters into a CRADA to Assess Efficacy of Brincidofovir for Epstein-Barr Virus Associated Lymphoproliferative Disease
2023.04.14
Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Directors
2023.04.14
Notice regarding the Issuance of Stock Acquisition Rights (Stock Options) to the Company’s Employees
2023.03.24
Notice of Shareholder Voting Results for the 18th Annual General Meeting of Shareholders
2023.03.23
Notice of Appointments to the Board of Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers
2023.03.23
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2023.03.23
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2023.03.22
Development of Brincidofovir for Multiple Sclerosis CRADA with the National Institute of Neurological Disorders and Stroke (NINDS)
2023.03.01
Information on Shareholders' Meeting: Updated the Page
2023.02.22
Notification of Amendment to the Articles of Incorporation
2023.02.09
Analyst Report[Flash report] (Shared Research)
2023.02.09
Summary of Financial Statements for the Fiscal Year Ended December 31, 2022 [Japanese GAAP] (Consolidated)
2023.02.09
Notice concerning non-operating expenses
2023.01.23
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2023.01.16
Analyst Report[Follow-up Report] (Fair Research)
2022.12.26
SymBio files lawsuit against Pfizer Japan Inc. for infringement of TREAKISYM patents
2022.12.19
SymBio enters into Sponsored Research Agreement for non-clinical study to verify the effectiveness of brincidofovir in a virus-infected brain tissue model
2022.12.16
SymBio files lawsuit for infringement of TREAKISYM patents
2022.12.14
SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV in Australia
2022.12.13
Presentation on the Anti-lymphoma Activity of Brincidofovir at the 64th ASH Annual Meeting
2022.12.12
Analyst Report[Full report] (Shared Research)
2022.11.24
SymBio enters into Material Transfer Agreement with Penn State College of Medicine for a non-clinical study to evaluate the efficacy of brincidofovir in a polyomavirus model
2022.11.08
Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.11.08
Revision to Earnings Forecast for FY 2022
2022.09.27
Chimerix announces closing of brincidofovir sale to Emergent BioSolutions
2022.08.31
Notice of Appointment of Corporate Officer
2022.08.22
SymBio submits clinical trial notification to TGA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation in Australia
2022.08.09
The National Institute of Neurological Disorders and Stroke and SymBio Pharmaceuticals Limited will collaborate to evaluate the potential antiviral activity of brincidofovir (BCV) against Epstein Barr virus (EBV)
2022.08.05
Analyst Report[Update report] (Shared Research)
2022.08.04
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.08.04
Revision to Earnings Forecast for FY 2022
2022.07.11
SymBio announces the publication of the results of its Phase I/II clinical study of the rapid infusion (RI) administration of TREAKISYM liquid formulation
2022.06.16
Notice of Resignation of Director
2022.06.14
SymBio submits clinical trial notification to PMDA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for patients with BK virus infection after renal transplantation
2022.06.13
SymBio announces status of market adoption of the 10-minute Rapid Infusion (RI) administration of the TREAKISYM Liquid Formulation
2022.06.08
Analyst Report[Basic Report] (Fair Research)
2022.06.03
Analyst Report[Full report] (Shared Research)
2022.06.01
Completion of Payment for the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.24
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2022.05.18
Chimerix announces sale of brincidofovir to Emergent BioSolutions
2022.05.16
Notice of the Issuance of New Shares and the 58th Stock Acquisition Rights through Third-party Allotment
2022.05.11
Summary of Financial Statements for the First Three Months of Fiscal Year Ending December 31, 2022 [Japanese GAAP] (Consolidated)
2022.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
2022.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
2022.04.01
Joint research agreement with the National Cancer Center on rare cancers
2022.03.31
Notice of Renewal of Syndicated Loan Agreement
2022.03.30
Notice of Shareholder Voting Results for the 17th Annual General Meeting of Shareholders
2022.03.29
Notice of Appointments to the Board of Directors and the Audit & Supervisory Committee, and Appointments of Corporate Officers
2022.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2022.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2022.03.25
Analyst Report[Full report] (Shared Research)
2022.03.09
Information on Shareholders' Meeting: Updated the Page
2022.03.08
SymBio announces publication the final results of its phase 3 clinical trial of TREAKISYM in r/r DLBCL
2022.03.07
SymBio announces initiation of non-clinical study of brincidofovir IV for brain tumors in collaboration with Brown University, USA
2022.02.28
SymBio receives approval of TREAKISYM Liquid Formulation Rapid Infusion (RI) administration
2022.02.25
Response to marketing approvals of generic products
2022.02.24
Notification of Amendments to the Articles of Incorporation
2022.02.24
Notice regarding the transition to a company with an audit and supervisory committee and nomination of directors
2022.02.24
SymBio announces results of a collaborative study with the National Institute of Infectious Diseases on adenoviruses and the antiviral agent brincidofovir
2022.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2021 [Japanese GAAP] (Non-consolidated)
2022.02.10
Notice concerning non-operating expenses
2022.02.10
Notice regarding difference between earnings forecast and the actual results for the fiscal year ended December 31, 2021
2022.01.31
Initiation of a phase 2 clinical trial of bendamustine and rituximab combination therapy followed by autologous hematopoietic stem cell transplantation in patients with relapsed or refractory diffuse large B-cell lymphoma
2022.01.18
SymBio submits clinical trial application to MHRA for Phase 2 clinical trial of anti-viral drug brincidofovir IV for treatment of pediatric adenovirus infection
2022.01.06
Joint research agreement to establish a Social Collaboration Course, Molecular Oncology, with the University of Tokyo
2021.12.24
Notice of Appointment of Executive Vice President, Corporate Officer and COO
2021.12.20
Notice of Appointment of Corporate Officer
2021.12.06
Analyst Report[Follow-up Report] (Fair Research)
2021.12.03
Analyst Report[Full report] (Shared Research)
2021.11.24
SymBio receives approval of shelf-life extension forTREAKISYM ready-to-dilute (RTD) liquid formulation
2021.11.11
Analyst Report[Update report] (Shared Research)
2021.11.11
Summary of Financial Statements for the Third Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.11.11
Notice Concerning Non-operating Expenses
2021.11.11
SymBio Achieves Operating Profit for the Nine Months Ending December 31, 2021 Financial Overview for the Third Quarter of the Fiscal Year
2021.11.11
SymBio announces selection of "Growth Market" as new market segment
2021.11.11
Message from President of SymBio Pharma USA
2021.10.12
SymBio announces commencement of operations of SymBio Pharma USA, Inc.
2021.09.29
SymBio announces presentation of the final results of its Phase 3 Clinical Trial of TREAKISYM in r/r DLBCL at the 83rd Annual Meeting of the Japanese Society of Hematology
2021.09.27
Onconova Therapeutics announces preliminary data on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
2021.09.21
Initiation of controls on shipments of TREAKISYM lyophilized injection formulation
2021.09.09
Analyst Report[Research Coverage Report] (Shared Research)
2021.09.08
SymBio announces initiation of non-clinical study of brincidofovir IV at the Brain Tumor Center, Department of Neurological Surgery University of California, San Francisco
2021.09.01
SymBio enters into a collaborative research agreement with the National Cancer Centre Singapore on Epstein-Barr virus positive lymphoma
2021.08.17
SymBio Announces First Patient Dosed in Phase 2 Clinical Trial of anti-viral drug Brincidofovir IV
2021.08.04
Analyst Report[Update report] (Shared Research)
2021.08.04
Notice Concerning Non-operating Expenses
2021.08.04
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.08.02
Collaborative research with Kyoto University on mechanism of response of bendamustine for diffuse large B-cell lymphoma
2021.07.15
Notice of Appointment of Corporate Officer
2021.07.15
Collaborative research with Gunma University to explore new indications for bendamustine and rigosertib
2021.06.29
Onconova Therapeutics announces an update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
2021.06.23
Notice of Changes of Director
2021.06.18
Onconova Therapeutics announces the synergistic anti-cancer activity of rigosertib combined with immune checkpoint blockade
2021.06.16
Analyst Report[Full report] (Shared Research)
2021.06.07
Chimerix receives U.S. Food and Drug Administration approval for brincidofovir for the treatment of smallpox
2021.06.01
Analyst Report[Basic Report] (Fair Research)
2021.05.25
New Patent Issued in Japan for Antiviral Agent Brincidofovir
2021.05.21
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2021.05.19
Chugai receives NHI price listing for polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.05.13
Analyst Report[Update report] (Shared Research)
2021.05.13
Notice of Appointment of Corporate Officer
2021.05.13
Summary of Financial Statements for the First Quarter of Fiscal Year Ending December 31, 2021 [Japanese GAAP] (Non-consolidated)
2021.05.10
SymBio submits a partial change application for use of TREAKISYM Liquid Formulation for Rapid Infusion (RI) administration
2021.04.28
SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.04.28
SymBio receives approval for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.04.26
U.S. Food and Drug Administration granted fast track designation to antiviral agent brincidofovir IV for the treatment of adenovirus infection in pediatric patients
2021.04.26
Onconova Therapeutics announces first patient dosed in an investigator-initiated Phase 2 study of rigosertib in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma
2021.04.23
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2021.04.23
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2021.03.29
SymBio submits partial change application to extend the shelf life of TREAKISYM Ready-To-Dilute (RTD) Formulation
2021.03.25
Notice of Shareholder Voting Results for the16th Ordinary General Meeting of Shareholders
2021.03.25
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.25
SymBio submits a partial change application for use of TREAKISYM Ready-To-Dilute (RTD) Formulation in combination with rituximab and polatuzumab vedotin for treatment of relapsed or refractory diffuse large B-cell lymphoma
2021.03.24
Notice of Appointments to the Board of Directors and the Audit & Supervisory Board, and Appointments of Corporate Officers
2021.03.24
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2021.03.24
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2021.03.23
SymBio receives approval for use of TREAKISYM in combination with rituximab and polatuzumab vedotin as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.23
SymBio receives approval for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2021.03.11
SymBio submits IND Application for Phase 2 Clinical Trial of Anti-viral Drug Brincidofovir IV for treatment of Pediatric Adenovirus Infection
2021.03.03
Information on Shareholders' Meeting: Updated the Page
2021.02.26
Chimerix Announces FDA Extends PDUFA Date of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox to July 7, 2021
2021.02.25
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2021.02.22
Results of Phase III Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2021.02.04
Analyst Report[Update report] (Shared Research)
2021.02.04
3 Year Mid-Range Plan: FY 2021 to FY 2023
2021.02.04
Notice Concerning Non-Operating Income
2021.02.04
Summary of Financial Statements for the Fiscal Year Ended December 31, 2020 [Japanese GAAP] (Non-consolidated)
2021.01.28
Collaborative research with the Institute of Medical Science, the University of Tokyo, to explore new indications for bendamustine and rigosertib
2021.01.12
Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.12.23
Notice of Appointment of Corporate Officer
2020.12.22
Notice of Conclusion of Syndicated Loan Agreement
2020.12.22
Analyst Report[Full report] (Shared Research)
2020.12.18
Completion, Monthly Exercise Status and Large Volume Exercise of the 51th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.12.10
Commencement of in-house sales of the anti-cancer agent Treakisym
2020.12.08
Chimerix Announces FDA Acceptance of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
2020.12.03
Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.12.01
Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.11.26
Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.11.24
National Health Insurance (NHI) Price Listing and Market Launch of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.11.11
Notice of the Large Volume Exercise of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.11.10
Analyst Report[Update report] (Shared Research)
2020.11.10
Summary of Financial Statements for the First Nine Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
2020.11.10
Notice Concerning Non-operating Expenses
2020.11.06
Chimerix Completed Rolling Submission of New Drug Application to FDA for Brincidofovir as a Medical Countermeasure for Smallpox
2020.11.04
Analyst Report[Follow-up Report] (Fair Research)
2020.11.02
Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.10.13
Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights
2020.09.23
SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.09.17
Analyst Report[Update report] (Shared Research)
2020.09.17
Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022)
2020.09.10
Analyst Report[Commercial outlook] (EDISON)
2020.09.09
Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation
2020.09.07
Preparation for Sales & Marketing by SymBio's Own Sales Organization
2020.09.01
Final Arbitration Award in Dispute against The Medicines Company
2020.08.25
Analyst Report[Full report] (Shared Research)
2020.08.25
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial for Higher-Risk Myelodysplastic Syndromes (HR-MDS)
2020.08.05
Analyst Report[Update report] (Shared Research)
2020.08.05
Arbitration Award in Dispute against The Medicines Company
2020.08.05
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
2020.08.05
Notice Concerning Non-operating Expenses
2020.08.05
SymBio Announces Global Development Plan of Anti-viral Drug Brincidofovir IV For Adenovirus Infectious DiseaseAfter Hematopoietic Stem Cell Transplantation
2020.07.30
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
2020.07.28
Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
2020.07.13
SymBio submits Partial Change Application for use of TREAKISYM in combination with polatuzumab vedotin and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2020.07.09
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
2020.06.23
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
2020.06.16
Analyst Report[Full report] (Shared Research)
2020.06.01
Completion, Monthly Exercise Status and Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.06.01
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.26
Analyst Report[Clinical update] (EDISON)
2020.05.19
Analyst Report[Earnings and regulatory update] (EDISON)
2020.05.15
The 25th Congress of the European Hematology Association (25th EHA Annual Congress) Accepts Abstract for Phase III Clinical Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma for Publication
2020.05.12
Analyst Report[Update report] (Shared Research)
2020.05.11
SymBio submits Partial Change Application for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2020.05.11
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.08
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.07
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.01
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.30
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
2020.04.30
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
2020.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
2020.04.22
Notice of Change (Retirement) of Director
2020.04.21
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.20
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2020.04.14
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.07
Analyst Report[Basic Report] (Fair Research)
2020.04.01
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.03.27
Notice of Shareholder Voting Results for the 15th Ordinary General Meeting of Shareholders
2020.03.26
Analyst Report[Full report] (Shared Research)
2020.03.26
Notice of Members of the Board of Director, Substitute Member of the Audit & Supervisory Board and Corporate Officers Appointment
2020.03.26
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2020.03.26
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2020.03.25
Completion of Patient Enrollment in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
2020.03.25
Onconova Announces Completion of Enrollment in Phase 3 INSPIRE Trial of IV Rigosertib
2020.03.16
Completion of Payment for Subscription for the 50th and 51st Stock Acquisition Rights (with Exercise Price Revision Clauses)
2020.03.06
Information on Shareholders' Meeting: Updated the Page
2020.02.27
Analyst Report[Update report] (Shared Research)
2020.02.27
Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)
2020.02.27
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2020.02.12
Completion, Monthly Exercise Status and Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.02.06
Analyst Report[Update report] (Shared Research)
2020.02.06
3 Year Mid-Range Plan: FY 2020 to FY 2022
2020.02.06
Notice Concerning Non-operating Expenses
2020.02.06
Summary of Financial Statements for the Fiscal Year Ended December 31, 2019[Japanese GAAP] (Non-consolidated)
2020.02.03
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.01.15
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.01.06
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.12.20
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2019.12.19
Notice of Appointment of Corporate Officer
2019.12.19
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.12.17
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.12.10
Onconova Announces Data from the INSPIRE Trial and Updated Oral Rigosertib Data at the American Society of Hematology (ASH) 2019 Annual Meeting
2019.12.09
Onconova Announces Collaboration with Inceptua for Pre-approval Access to Anti-cancer Drug Rigosertib
2019.12.02
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.12.02
Analyst Report[Full report] (Shared Research)
2019.11.27
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.11.25
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.11.12
Notice of Instruction for Front-Loading Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment and Conclusion of Amendment Agreement
2019.11.08
Analyst Report[Update report] (Shared Research)
2019.11.08
Summary of Financial Statements for the first nine months of fiscal year ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
2019.11.08
Notice Concerning Non-operating Expenses
2019.11.08
Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2019 ASH Annual Meeting & Exposition
2019.11.07
Analyst Report[Follow-up Report] (Fair Research)
2019.11.05
SymBio Announces Achievement of Primary Endpoint (Overall Response Rate) in Phase 3 Clinical Trial of TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
2019.10.25
Onconova Provides Update on the Global Phase 3 INSPIRE Trial of Rigosertib in Myelodysplastic Syndromes and on Future Clinical Trial Plans
2019.10.18
Notice Regarding Inappropriate Conduct of Clinical Trial Monitor
2019.10.01
SymBio Announces Exclusive Global License Agreement with Chimerix for Antiviral Drug, Brincidofovir
2019.09.26
SymBio Submits New Drug Application for TREAKISYM Ready-To-Dilute (RTD) Formulation
2019.09.25
Analyst Report[Full report] (Shared Research)
2019.09.18
Progress (LPLV) of Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM in relapsed/refractory diffuse large B-cell lymphoma
2019.08.07
Analyst Report[Update report] (Shared Research)
2019.08.07
Revision to Earnings Forecasts for FY 2019 and Mid-Range Plan (FY 2019 to FY 2022)
2019.08.07
Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
2019.08.07
Notice Concerning Non-operating Expenses
2019.07.19
Notice Regarding Sale of Fractional Shares Due to Reverse Stock Split
2019.07.01
Analyst Report[Full report] (Shared Research)
2019.06.17
Completion, Monthly Exercise Status and Large Volume Exercise of the 46th Stock Acquisition Rights(with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.06.13
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.06.12
Notice of Change (Resignation) of Representative Director and Appointment of Corporate Officer
2019.06.11
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.06.03
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.05.28
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.05.22
Launch of "Regenerative Medicine" Products that can be used with the anti-cancer drug TREAKISYM as a pretreatment agent
2019.05.14
Analyst Report[Update report] (Shared Research)
2019.05.14
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2019 [Japanese GAAP] (Non-consolidated)
2019.05.14
Notice Concerning Non-operating Expenses
2019.05.07
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2019.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2019.04.18
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.17
Analyst Report[Corporate outlook] (EDISON)
2019.04.16
Analyst Report[Basic Report] (Fair Research)
2019.04.12
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.10
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.10
First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
2019.04.08
Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2019.04.03
Analyst Report[Full report] (Shared Research)
2019.04.01
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.01
Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib
2019.03.29
Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders
2019.03.28
Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
2019.03.28
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2019.03.28
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2019.03.28
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
2019.03.26
TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy
2019.03.14
Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.03.11
Information on Shareholders' Meeting: Updated the Page
2019.03.05
(Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
2019.02.28
Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation
2019.02.28
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2019.02.07
SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years)
2019.02.07
Notice Concerning Non-operating Expenses
2019.02.07
Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated)
2018.12.20
Shipments of the 25mg Presentation of Anti-cancer Drug TREAKISYM Intravenous Infusion Paused and Shipment of Substitute
2018.12.17
Completion of Exercise of the 39th Stock Acquisition Rights Issued by way of Third Party Allotment
2018.12.12
Analyst Report[Strategy update]（EDISON)
2018.12.07
Analyst Report[Full report] (Shared Research)
2018.12.04
Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting
2018.11.30
Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation)
2018.11.09
Analyst Report[Update report]: Shared Research updates the report
2018.11.09
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
2018.11.08
Analyst Report[Follow-up Report] (Fair Research)
2018.11.06
Onconova Announces Presentation on Rigosertib in Myelodysplastic Syndromes at 2018 ASH Annual Meeting & Exposition
2018.10.17
Onconova Announces Issuance of a New U.S. Patent for Rigosertib
2018.10.16
SymBio Begins Preparation for Own Sales Organization for the Anti-Cancer Agent TREAKISYM
2018.10.01
Completion and Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.10.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.09.27
SymBio files Partial Change Application for use of TREAKISYM as a Pretreatment to Regenerative Medical Products
2018.09.25
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.09.05
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.09.03
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.08.30
Analyst Report[Full report] (Shared Research)
2018.08.29
Launch of New Anti-CD20 Antibodies that can be used in combination with the anti-cancer agent TREAKISYM
2018.08.29
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.08.21
Analyst Report[Basic Report] (Fair Research)
2018.08.07
Analyst Report[Update report]: Shared Research updates the report
2018.08.07
Notice Concerning Non-operating Expenses
2018.08.07
Summary of Financial Results for the First Half of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
2018.08.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.07.30
Revised Medical Practice Guidelines 2018 for Healthcare Professionals
2018.07.25
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.07.09
Eagle Announces New Patent Issued for Bendamustine Hydrochloride Injection in the U.S.
2018.07.04
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.07.02
TREAKISYM Receives Approval for Combined Use with Anti-CD20 Antibodies
2018.07.02
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.06.18
Eagle Announces U.S. Court Decision Granting Orphan Drug Exclusivity for Bendamustine Hydrochloride Injection in the U.S.
2018.06.06
Notice of the Large Volume Exercise of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.06.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.05.28
Analyst Report[Full report]: Shared Research updates the report
2018.05.28
First Patient Enrolled in Phase 1 Clinical Trial for Oral TREAKISYM for Progressive Solid Tumors
2018.05.18
TREAKISYM Sales Forecast for FY2018
2018.05.10
Analyst Report[Update report]: Shared Research updates the report
2018.05.10
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2018 [Japanese GAAP] (Non-consolidated)
2018.05.10
Notice Concerning Non-operating Expenses
2018.05.10
Initiation of Collaborative Research with Keio University on TREAKISYM for Systemic Lupus Erythematosus
2018.05.01
Monthly Exercise Status of the 45th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2018.04.26
(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2018.04.26
(Correction Notice of Press Release) Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2018.04.26
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2018.04.26
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2018.04.25
Completion of Payment for Subscription for the 45th through 47th Stock Acquisition Rights (with Exercise Price Revision Clauses)
2018.04.18
TREAKISYM Achieves 50% Market Share for 1st Line Low Grade Non-Hodgkin Lymphoma
2018.04.09
Analyst Report[Update report]: Shared Research updates the report
2018.04.09
Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Commit Issue Program) and Conclusion of an Unsecured Loan Facility Agreement
2018.03.30
Notice of Shareholder Voting Results for the 13th Ordinary General Meeting of Shareholders
2018.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2018.03.29
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2018.03.29
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
2018.03.27
Analyst Report[Full report]: Shared Research updates the report
2018.03.13
Information on Shareholders' Meeting: Updated the Page
2018.03.06
Notice concerning Nominations for the Board of Directors/the Audit & Supervisory Board/and Substitute Member for the Audit & Supervisory Board
2018.02.19
Analyst Report[Basic Report]: Fair Research updates the report
2018.02.09
Termination of the Development of the Patient-controlled Pain Management Drug "SyB P-1501"
2018.02.07
Analyst Report[Update report]: Shared Research updates the report
2018.02.07
SymBio's Mid-Range Plan: FY2018 to FY2021
2018.02.07
Summary of Financial Statements for the Fiscal Year Ended December 31, 2017 [Japanese GAAP] (Non-consolidated)
2018.02.07
Notice Concerning Non-Operating Income
2018.01.22
Initiation of Phase 1 Clinical Trial for Oral TREAKISYM in Progressive Solid Tumors
2018.01.18
Onconova Announces Plans for the Global Randomized Phase 3 Trial of IV Rigosertib after Promising Interim Analysis
2017.12.08
Analyst Report[Full report]: Shared Research updates the report
2017.11.30
Termination of License Agreement between SymBio Pharmaceuticals Limited and The Medicines Company
2017.11.13
Initiation of an Arbitration against The Medicines Company
2017.11.10
Analyst Report[Update report]: Shared Research updates the report
2017.11.10
Notice Concerning Non-operating Income
2017.11.10
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2017 [Japanese GAAP] (Non-consolidated)
2017.11.02
Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at 2017 ASH Annual Meeting
2017.10.23
Analyst Report: Edison updates the report
2017.10.16
Analyst Report[Full report]: Shared Research updates the report
2017.10.10
Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.09.21
Analyst Report[Update report]: Shared Research updates the report
2017.09.21
Notice of Revision to the Earnings Forecast for FY2017
2017.09.21
Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
2017.09.20
Analyst Report[Full report]: Shared Research updates the report
2017.08.31
Initiation in Japan of the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2017.08.30
Application for Partial Change of Marketing Approvals for the Anti-cancer Drug TREAKISYM
2017.08.25
Completion of Payment for Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Notice of the Subscription for the 42nd Stock Acquisition Rights by Third-Party Allotment
2017.08.09
Current Status of the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.08.03
Analyst Report[Update report]: Shared Research updates the report
2017.08.03
Notice Concerning Non-operating Income
2017.08.03
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
2017.07.26
Onconova Announces Establishment of Collaborative Research and Clinical Program Evaluating Rigosertib in Pediatric "RASopathies"
2017.07.05
Dr. Koichi Takahashi, Assistant Professor, The University of Texas MD Anderson Cancer Center, has been appointed as a member of the SAB.
2017.06.30
Initiation in Japan of the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes
2017.06.05
SEC Filing by The Medicines Company as the Licensor of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.06.05
Analyst Report[Full report]: Shared Research updates the report
2017.05.11
Analyst Report[Update report]: Shared Research updates the report
2017.05.11
Summary of Financial Results for the First Quarter of Fiscal Year Ending December 31, 2017[Japanese GAAP] (Non-consolidated)
2017.05.11
Notice Concerning Non-operating Expenses
2017.05.11
Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial of the Patient-controlled Pain Management Drug "SyB P-1501"
2017.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2017.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2017.03.30
Notice of Shareholder Voting Results for the 12th Ordinary General Meeting of Shareholders
2017.03.29
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
2017.03.29
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
2017.03.29
Notice of Appointment of Members of the Board of Directors, Members of the Audit & Supervisory Board, and the Corporate Officers
2017.03.28
Analyst Report[Full report]: Shared Research updates the report
2017.03.06
Information on Shareholders' Meeting: Updated the Page
2017.02.24
Notice concerning the Appointment of the Representative Director and Nominations for the Board of Directors/ Auditor Candidates
2017.02.24
Notice of Change to Use of Funds from the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights Issued by Third-Party Allotment
2017.02.09
Analyst Report[Update report]: Shared Research updates the report
2017.02.09
SymBio's Mid-Range Plan: FY2017 to FY2019
2017.02.09
Summary of Financial Statements for the Fiscal Year Ended December 31, 2016[Japanese GAAP] (Non-consolidated)
2017.02.09
Notice Concerning Non-Operating Income
2017.02.01
Expiration of the Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
2016.12.19
Analyst Report: Shared Research updates the report
2016.12.19
Approval in Japan of the Anti-cancer Drug TREAKISYM® for the Additional Indication of First-line Treatment of Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
2016.12.06
Onconova Presents Phase 2 Data from Oral Rigosertib and Azacitidine Combination Trial in Higher-Risk Myelodysplastic Syndromes at 2016 ASH Annual Meeting
2016.11.22
Initiation of Patient Enrollment in the Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
2016.11.14
Notice of Shareholder Voting Results for the Extraordinary Shareholders' Meeting
2016.11.11
Analyst Report: Shared Research updates the report
2016.11.11
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.11.11
Notice concerning Non-operating Expenses
2016.10.20
Information on The Extraordinary Shareholders' Meeting: Updated the Page
2016.10.03
Notice concerning the Change in Major and Largest Shareholder among the Company's Major Stockholders
2016.09.28
Approval in Japan of the Anti-cancer Drug TREAKISYM® Intravenous Infusion 25 mg
2016.09.27
Onconova Announces Results of End-of-Phase 2 Meeting with FDA regarding Plans for Pivotal Phase 3 Oral Rigosertib/Azacitidine Combination Trial for Higher-risk Myelodysplastic Syndromes
2016.09.15
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
2016.09.15
Notice concerning Partial Amendment to the Articles of Incorporation
2016.09.12
Analyst Report: Shared Research updates the report
2016.08.26
Approval of the Anti-cancer Drug TREAKISYM® for the Additional Indication of Chronic Lymphocytic Leukemia
2016.08.04
Analyst Report: Shared Research updates the report
2016.08.04
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.08.04
Notice Concerning Non-operating Expenses
2016.07.19
Initiation of Patient Enrollment in Japan for the Global Randomized Phase 3 Trial of IV Rigosertib for Higher-risk Myelodysplastic Syndromes (MDS)
2016.06.16
Corporate governance policies
2016.06.14
Onconova Announces Presentation of Clinical Data from Oral Rigosertib/Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
2016.06.13
Analyst Report: Shared Research updates the report
2016.06.13
Initiation of Phase 3 Clinical Trial on the Patient-controlled Pain Management Drug "SyB P-1501"
2016.06.08
Notice concerning the Change of Major Shareholder
2016.06.07
Onconova Announces Poster Presentations for Oral Rigosertib/Azacitidine Combination and IV Rigosertib at 2016 ASCO Annual Meeting
2016.06.02
Onconova Announces Upcoming Rigosertib Clinical Trial Presentations for 2016 ASCO Annual Meeting
2016.05.30
Notice concerning the Change of Major Shareholder
2016.05.24
Notice concerning the Change of Major Shareholder
2016.05.20
Notice concerning Cancellation of the Extraordinary Shareholders' Meeting on July 15, 2016 and Cancellation of the Record Date therefor
2016.05.19
Notice concerning the Change of Major and Largest Shareholder among the Company's Major Stockholders
2016.05.11
SymBio Announces Incorporation of its U.S. Subsidiary
2016.05.10
Analyst Report: Shared Research updates the report
2016.05.10
Notice of the Setting of the Record Date in respect of the Convocation of the Extraordinary Shareholders' Meeting
2016.05.10
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2016[Japanese GAAP](Non-consolidated)
2016.05.10
Notice Concerning Non-operating Expenses
2016.04.22
Completion of Payment for Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
2016.04.14
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2016.04.14
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2016.04.06
Analyst Report: Shared Research updates the report
2016.04.06
Notice of the Issuance of and the Subscription for the 3rd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 39th Stock Acquisition Rights by Third-Party Allotment
2016.03.31
(Correction) Notice concerning partial correction to the "Notice of Appointment of Directors"
2016.03.31
Notice of Shareholder Voting Results for the 11th Ordinary General Meeting of Shareholders
2016.03.30
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Directors
2016.03.30
Notice Concerning the Issuance of Stock Acquisition Rights (Stock Option) to Employees
2016.03.30
Notice of Appointment of Directors
2016.03.23
Analyst Report: Edison updates the report
2016.03.21
Analyst Report: Edison updates the report
2016.03.17
Analyst Report: Shared Research updates the report
2016.03.11
Information on Shareholders' Meeting: Updated the Page
2016.03.10
Notice concerning Partial Amendment to the Articles of Incorporation and Nomination of Director Candidates
2016.03.10
Onconova Announces Publication of Results from the ONTIME Trial for rigosertib in MDS
2016.02.10
Analyst Report: Shared Research updates the report
2016.02.10
SymBio's Long Range Plan: FY2016 to FY2018
2016.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2015[Japanese GAAP] (Non-consolidated)
2016.02.10
Notice Concerning Non-operating Expenses
2016.02.08
SymBio and Teikyo Heisei University enter into a Joint Research and Development Agreement for an Anti-cancer Drug using the TTR1 Nano-agonist Molecule
2016.02.04
Assessment Status of Bendamustine in Europe
2015.12.28
SymBio starts Global Phase 3 Trial for IV Rigosertib
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in First-Line Low-grade NHL and MCL
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in Chronic Lymphocytic Leukemia (Additional Indication)
2015.12.24
SymBio Files Supplemental NDA for TREAKISYM® in a 25mg Vial (Different Strength)
2015.12.08
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
2015.12.08
Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib
2015.12.07
Analyst Report: Shared Research updates the report
2015.12.07
Start of Japan Phase I Combination Clinical Trial of Oral Rigosertib and Azacytidine in Higher-risk MDS
2015.12.01
Analyst Report: Edison updates the report
2015.11.30
Analyst Report: Edison updates the report
2015.11.24
SymBio Partner Announces European Approval of IONSYS®
2015.11.06
Analyst Report: Shared Research updates the report
2015.11.06
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.11.06
Notice Concerning Non-operating Expenses
2015.10.30
Completion of Japan Phase 1 Clinical Trial for IV Rigosertib in MDS
2015.10.19
Completion of TREAKISYM® Phase II Trial in Chronic Lymphocytic Leukemia
2015.10.19
SymBio to Participate in Global Phase 3 Trial for IV Rigosertib
2015.10.06
The article regarding "Establishment of Strategic Partnership for IONSYS® between The Medicines Company and SymBio" was posted on WSJ
2015.10.05
SymBio and The Medicines Company (Nasdaq: MDCO), announce the establishment of a strategic partnership for IONSYS® (fentanyl iontophoretic transdermal system) in Japan.
2015.09.03
Analyst Report: Shared Research updates the report
2015.08.28
Onconova Announces Submission of European Clinical Trial Applications for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
2015.08.17
Onconova to Present Results from Phase 2 Study of Oral Rigosertib in Combination with Azacitidine for MDS and AML Patients
2015.08.17
Onconova Announces Submission of IND for IV Rigosertib Pivotal Phase 3 Trial in Higher-Risk MDS
2015.08.05
Analyst Report: Shared Research updates the report
2015.08.05
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.08.05
Notice Concerning Non-operating income
2015.06.26
Completion of Japan Phase I Trial for Oral Rigosertib (SyB C-1101) in MDS
2015.05.07
Analyst Report: Shared Research updates the report
2015.05.07
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2015[Japanese GAAP](Non-consolidated)
2015.05.07
Notice Concerning Non-operating Expense
2015.04.10
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2015.04.10
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2015.03.27
Notice of Shareholder Voting Results for the 10th Ordinary General Meeting of Shareholders
2015.03.26
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
2015.03.26
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
2015.03.26
Notice of Director and Auditor Appointments
2015.03.23
Analyst Report: Shared Research updates the report
2015.03.18
Notice Concerning Change in Status of Major shareholder
2015.03.06
Information on Shareholders' Meeting: Updated the Page
2015.03.05
Notice of Nomination of Director Candidates and Auditor Candidates
2015.02.12
Analyst Report: Shared Research updates the report
2015.02.10
SymBio's Long Range Plan: FY2015 to FY2017
2015.02.10
Summary of Financial Statements for the Fiscal Year Ended December 31, 2014[Japanese GAAP] (Non-consolidated)
2015.02.10
Notice Concerning Non-Operating Income
2015.02.03
Onconova Announces its Clinical Development Plan for Rigosertib in MDS
2015.01.26
Establishment of Sponsored ADR (American Depositary Receipt) Program
2015.01.13
SEC filings for Establishment of Sponsored ADR (American Depositary Receipt) Program
2015.01.13
Completion of Patient Enrollment of rigosertib (SyB L-1101, IV) Phase I Trial in Patient with refractory or relapsed myelodysplastic syndrome (MDS)
2014.12.24
Notice of Revision of the Long Range Plan: FY2014 to FY2016
2014.12.24
SymBio's Long Range Plan: FY2014 to FY2016 (Revised Version)
2014.12.01
Analyst Report: Shared Research initiates coverage on SymBio
2014.12.01
Completion of Payment for Subscription of the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
2014.11.14
Notice of the Subscription for the 2nd Unsecured Bonds with Convertible Bond Type Stock Acquisition Rights and the 34th Stock Acquisition Rights by Third-Party Allotment
2014.11.13
Notice of Revision of the Financial Forecast for FY2014
2014.11.07
Notice Concerning Non-Operation Income
2014.11.07
Summary of Financial Results For the Third Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
2014.11.06
Completion of Patient Enrollment of TREAKISYM® Phase II Trial in Patient with Chronic Lymphocytic Leukemia (CLL)
2014.10.13
Analyst Report: Edison initiates coverage on SymBio
2014.09.19
Notice Concerning Change in Status of Major shareholder
2014.09.18
Notice Concerning Relocation of Head Office
2014.08.14
Onconova's Announcement in the Development of Rigosertib for patients with MDS in Second Quarter 2014
2014.08.06
Notice Concerning Non-Operation Expense
2014.08.06
Summary of Financial Results For the Second Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
2014.06.18
SymBio Announces Korea NDA Approval of Additional Indication for Bendamustine Hydrochloride (SyB L-0501)
2014.05.08
Notice Concerning Non-Operation Expense
2014.05.08
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2014[Japanese GAAP](Non-consolidated)
2014.04.30
Notice Concerning Adjustment to Exercise Price of Stock Option
2014.04.30
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2014.04.30
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2014.04.15
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Employees
2014.04.15
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
2014.03.28
Notice of Shareholder Voting Results for the 9th Ordinary General Meeting of Shareholders
2014.03.27
Notice Concerning the Appointment of Directors
2014.03.27
Announcement Personnel Changes
2014.03.06
Notice Concerning the Partial Amendment to the Articles of Incorporation and Election of Directors
2014.03.06
Notice Concerning the Issuance of Stock Acquisition Rights as Stock Option to Directors
2014.02.20
Onconova Announces Results from Phase 3 ONTIME Study of Rigosertib in Higher Risk Myelodysplastic Syndromes (MDS)
2014.02.20
SymBio's Long Range Plan: FY2014 to FY2016
2014.02.12
Summary of Financial Statements for the Fiscal Year Ended December 31, 2013[Japanese GAAP](Non-consolidated)
2013.12.18
Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study
2013.12.10
Onconova Presents Phase 2 Data for Oral Rigosertib at 2013 American Society of Hematology Annual Meeting
2013.11.27
SymBio Announces Pricing of Secondary Offering and Overallotment
2013.11.19
SymBio Announces Issuance of New Shares and Secondary Offering of Shares
2013.11.14
Onconova Therapeutics, Inc. Reports Third Quarter 2013 Financial and Operational Results
2013.11.08
Summary of Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-Consolidated)
2013.11.01
TREAKISYM® PhaseⅡ Trial in Multiple Myeloma
2013.10.18
Dr. George Morstyn (outside Board Director) has been elected a fellow of ATSE (The Australian Academy of Technological Sciences and Engineering).
2013.08.07
Summary of Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-Consolidated)
2013.07.26
SymBio Announces Revised Financial Forecast
2013.06.03
Onconova Presents Phase II Data for Oral Rigosertib at 2013 American Society of Clinical Oncology Annual Meeting - Oral Rigosertib (ON 01910.Na) in Transfusion-Dependent Lower Risk MDS
2013.05.14
Summary of Financial Results For the First Quarter of Fiscal Year Ending December 31, 2013[Japanese GAAP](Non-consolidated)
2013.05.10
Onconova Completes Enrollment in ONTIME Pivotal Phase 3 Study of Rigosertib in Patients with High-risk Myelodysplastic Syndromes
2013.05.08
SymBio Initiates Japanese Phase II Trial for TREAKISYM® (Bendamustine) in CLL
2013.05.07
JCO (Journal of Clinical Oncology)- Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2013.03.28
Dr. Milton H. Grannatt Joins SymBio as Outside Director
2013.03.26
SymBio Initiates Japanese Phase I Trial of Oral rigosertib (SyB C-1101) in Frontline MDS
2013.03.15
SYMBIO AND EISAI ANNOUNCE REMOVAL OF TREAKISYM® INJECTION 100 MG ALL CASES SURVEILLANCE CONDITION FOR JAPAN MARKETING APPROVAL
2013.03.06
Completion of Patient Enrollment of TREAKISYM® (SyB L-0501) Phase II Trial in Frontline Low-grade Non-Hodgkin’s Lymphoma and Mantle Cell Lymphoma
2013.02.20
The Lancet(Online First) - Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
2013.02.14
Summary of Financial Statements for the Fiscal Year Ended December 31, 2012 [Japanese GAAP] (Non-consolidated)
2013.01.28
SymBio Completes Phase 2 Trial of Antiemetic Transdermal Patch (SyB D-0701) in RINV
2013.01.07
SymBio Receives Clinical Trial Notification Acceptance for Phase 2 TREAKISYM® (Bendamustine) Trial in CLL
2012.12.27
Notice of Issuance of 1st Unsecured Convertible Bond with Stock Acquisition Rights and 29th Warrant by Third-Party Allotment
2012.12.27
Clinical Trial Notification Accepted by Japanese Regulatory Agency for SymBio's Phase I Oral Rigosertib (SyB C-1101) Trial in Frontline MDS
2012.11.09
SymBio Announces Revised Financial Forecast
2012.11.09
Financial Results for the Third Quarter of Fiscal Year Ending December 31, 2012 [Japan GAAP] (Non-consolidated)
2012.10.24
SymBio Announces Completion of Patient Enrollment for Phase II Clinical Trial of SyB D-0701 in RINV
2012.09.20
Onconova Closes Deal with Baxter (BAX) for Rigosertib in Europe
2012.08.08
Financial Results for the Second Quarter of Fiscal Year Ending December 31, 2012 [Japan GAAP] (Non-consolidated)
2012.06.29
SymBio Initiates Japanese Phase I Trial of Rigosertib (SYB L-1101) in Relapsed/Refractory MDS
2012.06.14
SymBio Announces Orphan Drug Designation for TREAKISYM® (Bendamustine) in Chronic Lymphocytic Leukemia (CLL)
2012.06.04
SymBio Announces Results Presented at ASCO 2012 Evaluating Clinical Benefits of TREAKISYM® (Bendamustine) in Combination with Rituximab in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
2012.06.01
SymBio Announces Data Presentations at 48th Annual American Society of Clinical Onoclogy Meeting
2012.05.30
SymBio Announces Development Status of TREAKISYM® in Refractory and Relapsed Aggressive Non-Hodgkin's Lymphoma
2012.05.15
Onconova Advances Oral Rigosertib to Phase II Clinical Trial in Myelodysplastic Syndromes
2012.05.11
Financial Results for the First Quarter of Fiscal Year Ended December 31, 2012 [Japan GAAP] (Non-consolidated)
2012.04.16
SymBio Announces Presentation at BioCentury Future Leaders in the Biotech Industry Conference
2012.03.29
Clinical Trial Notificaation Accepted for SymBio's Japan Phase 1 Trial of Rigosertib(SyB L-1101) in Refractory/Relapsed MDS
2012.03.09
7th Term General Shareholders' Meeting
2012.02.24
SymBio Announces Bendamustine Hydrochloride(SyB L-0501) Launch in Taiwan
2012.02.14
Summary of Financial Statements for the Fiscal Year Ended December 31, 2011 [Japan GAAP](Non-consolidated)
2011.12.26
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Multiple Myeloma
2011.12.13
Onconova Presents Phase Ⅰ Data for Oral Rigosertib at the 53rd American Society of Hematology Annual Meeting
2011.11.14
Clinical Trial Notification Accepted for SymBio's Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Multiple Myeloma
2011.11.11
Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2011
2011.11.10
SymBio Initiates Japan Phase 2 Trial of Bendamustine HCI(SyB L-0501) in Frontline Low-grade Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
2011.10.25
Results of Third Party Allocation of New Shares
2011.10.21
SymBio Announces Taiwan NDA Approval of Bendamustine Hydrochloride(SyB L-0501)
2011.10.20
SymBio Pharmaceuticals Limited was listed on Osaka Securities Exchange JASDAQ Growth Market
2011.10.20
Financial Disclosure for SymBio’s New Listing on Osaka Securities Exchange JASDAQ Growth Market
2011.10.19
Homepage renewal
2011.10.11
Determination of Issuance Price Per Share, Equity Offering Price and Number of Shares by Overallotment
2011.09.29
Amount to Be Paid for New Shares and Tentative Terms for Book Building
2011.09.14
Corporate Resolution for SymBio’s Initial Public Offering of Shares on JASDAQ
2011.08.26
BioCentury article on Rigosertib deal between SymBio and Onconova
2011.07.11
Onconova and SymBio Complete License Agreement for Rigosertib, a Phase Ⅲ Stage Multi-Kinase Inhibitor for Cancer
2011.06.03
SymBio Announces Korea NDA Approval of Bendamustine Hydrochloride (SyB L-0501)
2011.05.11
The news of Human Resources
2011.02.25
SymBio Pharmaceuticals Successfully Completes JPY2.0 Billion (USD24 Million) Series E Private Placement